Cargando…

Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease

OBJECTIVE: An increased risk of multiple myeloma (MM) has been observed among individuals with low pre-diagnostic circulating levels of adiponectin, a metabolic hormone that is typically underexpressed among those who are overweight or obese. To assess whether adiponectin may influence myeloma devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmann, Jonathan N, Mailankody, Sham, Korde, Neha, Wang, Ye, Tageja, Nishant, Costello, Rene, Zingone, Adriana, Hultcrantz, Malin, Pollak, Michael N, Purdue, Mark P, Landgren, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611818/ https://www.ncbi.nlm.nih.gov/pubmed/28602036 http://dx.doi.org/10.1002/oby.21894

Ejemplares similares

Dietary intake is associated with risk of multiple myeloma and its precursor disease
por: Thordardottir, Marianna, et al.
Publicado: (2018)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
por: Landgren, O, et al.
Publicado: (2017)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2019)

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2020)

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
por: Lindqvist, Ebba K., et al.
Publicado: (2016)

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021)

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster
por: Landgren, Ola, et al.
Publicado: (2018)

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
por: Chang, Vicky C., et al.
Publicado: (2022)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
por: Oben, Bénedith, et al.
Publicado: (2021)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2021)

Circulating resistin levels and risk of multiple myeloma in three prospective cohorts
por: Santo, Loredana, et al.
Publicado: (2017)

Nutrition perceptions, needs and practices among patients with plasma cell disorders
por: Malik, Maria A., et al.
Publicado: (2022)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

Biological determinants of health disparities in multiple myeloma
por: Smith, Cheryl Jacobs, et al.
Publicado: (2018)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2019)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

Serum leptin and adiponectin levels and risk of renal cell carcinoma
por: Liao, Linda M, et al.
Publicado: (2013)

Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster
por: Zeig-Owens, Rachel, et al.
Publicado: (2022)

Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed
por: Tageja, Nishant, et al.
Publicado: (2010)

Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology—A Case Report
por: Tageja, Nishant, et al.
Publicado: (2010)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies
por: Mailankody, Sham, et al.
Publicado: (2016)

AutoCAD electrical 2010 for electrical control designers
por: Purdue, Sham Tickoo
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7qgssq9mscon9b7qabutth1smd